A versatile platform technology for recombinant vaccines using non-propagative human parainfluenza virus type 2 vector.
Animals
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
Chlorocebus aethiops
Epitopes
/ genetics
Gene Order
Genetic Engineering
Genetic Vectors
/ genetics
Humans
Mice
Neutralization Tests
Parainfluenza Virus 2, Human
/ genetics
T-Lymphocyte Subsets
/ immunology
Vaccines, Synthetic
/ genetics
Vaccinology
/ methods
Vero Cells
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 09 2019
09 09 2019
Historique:
received:
09
10
2018
accepted:
11
07
2019
entrez:
11
9
2019
pubmed:
11
9
2019
medline:
28
10
2020
Statut:
epublish
Résumé
Ectopic protein with proper steric structure was efficiently loaded onto the envelope of the F gene-defective BC-PIV vector derived from human parainfluenza virus type 2 (hPIV2) by a reverse genetics method of recombinant virus production. Further, ectopic antigenic peptide was successfully loaded either outside, inside, or at both sides of the envelope of the vector. The BC-PIV vector harboring the Ebola virus GP gene was able to elicit neutralizing antibodies in mice. In addition, BC-PIV with antigenic epitopes of both melanoma gp100 and WT1 tumor antigen induced a CD8+ T-cell-mediated response in tumor-transplanted syngeneic mice. Considering the low pathogenicity and recurrent infections of parental hPIV2, BC-PIV can be used as a versatile vector with high safety for recombinant vaccine development, addressing unmet medical needs.
Identifiants
pubmed: 31501502
doi: 10.1038/s41598-019-49579-y
pii: 10.1038/s41598-019-49579-y
pmc: PMC6733870
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Epitopes
0
Vaccines, Synthetic
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12901Références
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11359-65
pubmed: 8876140
Virol Sin. 2017 Feb;32(1):3-15
pubmed: 27853993
Science. 2015 Aug 14;349(6249):739-42
pubmed: 26249231
J Virol. 2003 Jul;77(13):7539-44
pubmed: 12805454
J Virol. 2011 Jun;85(11):5406-14
pubmed: 21411529
Biochem Biophys Res Commun. 1994 Aug 15;202(3):1235-43
pubmed: 8060298
Nature. 2015 Apr 30;520(7549):688-691
pubmed: 25853476
Arch Virol. 1989;108(1-2):137-44
pubmed: 2480761
Virology. 2009 Jan 20;383(2):348-61
pubmed: 19010509
J Virol. 1999 Oct;73(10):8907-12
pubmed: 10482652
Clin Microbiol Rev. 2003 Apr;16(2):242-64
pubmed: 12692097
Rev Med Virol. 2018 Mar;28(2):
pubmed: 29316047
Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14764-9
pubmed: 9405687
J Infect Dis. 2007 Nov 15;196 Suppl 2:S347-56
pubmed: 17940970
Virology. 2001 May 25;284(1):99-112
pubmed: 11352671
J Virol. 2013 Mar;87(6):3324-34
pubmed: 23302883
Gene Ther. 2014 Aug;21(8):775-84
pubmed: 24942630
Curr Top Microbiol Immunol. 2004;283:1-41
pubmed: 15298166
Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1893-8
pubmed: 23319647
Hum Gene Ther. 2013 Jul;24(7):683-91
pubmed: 23790317
Nature. 2008 Jul 10;454(7201):177-82
pubmed: 18615077
J Virol. 2016 Oct 14;90(21):10022-10038
pubmed: 27581977
J Virol. 2017 Apr 28;91(10):
pubmed: 28250127
Med Microbiol Immunol. 1999 Nov;188(2):79-82
pubmed: 10753059